These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

602 related items for PubMed ID: 27780368

  • 1. Alectinib for treatment of ALK-positive non-small-cell lung cancer.
    Avrillon V, Pérol M.
    Future Oncol; 2017 Feb; 13(4):321-335. PubMed ID: 27780368
    [Abstract] [Full Text] [Related]

  • 2. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
    Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T.
    Lancet; 2017 Jul 01; 390(10089):29-39. PubMed ID: 28501140
    [Abstract] [Full Text] [Related]

  • 3. Alectinib for ALK-positive non-small-cell lung cancer.
    Rossi A.
    Expert Rev Clin Pharmacol; 2016 Aug 01; 9(8):1005-13. PubMed ID: 27232673
    [Abstract] [Full Text] [Related]

  • 4. Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer.
    Wong KM, Noonan S, O'Bryant C, Jimeno A.
    Drugs Today (Barc); 2015 Mar 01; 51(3):161-70. PubMed ID: 25876560
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH.
    Lancet Oncol; 2014 Sep 01; 15(10):1119-28. PubMed ID: 25153538
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer.
    Santarpia M, Altavilla G, Rosell R.
    Expert Rev Respir Med; 2015 Jun 01; 9(3):255-68. PubMed ID: 25652176
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
    Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T, ALEX Trial Investigators.
    N Engl J Med; 2017 Aug 31; 377(9):829-838. PubMed ID: 28586279
    [Abstract] [Full Text] [Related]

  • 11. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.
    Kodama T, Tsukaguchi T, Yoshida M, Kondoh O, Sakamoto H.
    Cancer Lett; 2014 Sep 01; 351(2):215-21. PubMed ID: 24887559
    [Abstract] [Full Text] [Related]

  • 12. Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.
    Kogita A, Togashi Y, Hayashi H, Banno E, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Takeyama Y, Okuno K, Nakagawa K, Nishio K.
    Int J Oncol; 2015 Mar 01; 46(3):1025-30. PubMed ID: 25502629
    [Abstract] [Full Text] [Related]

  • 13. Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.
    Zhu V, Ou SH.
    Expert Opin Drug Saf; 2017 Apr 01; 16(4):509-514. PubMed ID: 28276856
    [Abstract] [Full Text] [Related]

  • 14. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
    Gadgeel SM.
    Future Oncol; 2018 Aug 01; 14(18):1875-1882. PubMed ID: 29536761
    [Abstract] [Full Text] [Related]

  • 15. Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.
    McKeage K.
    Drugs; 2015 Jan 01; 75(1):75-82. PubMed ID: 25428710
    [Abstract] [Full Text] [Related]

  • 16. ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.
    Ou SH, Milliken JC, Azada MC, Miller VA, Ali SM, Klempner SJ.
    Lung Cancer; 2016 Jan 01; 91():70-2. PubMed ID: 26464158
    [Abstract] [Full Text] [Related]

  • 17. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
    Ou SH, Greenbowe J, Khan ZU, Azada MC, Ross JS, Stevens PJ, Ali SM, Miller VA, Gitlitz B.
    Lung Cancer; 2015 May 01; 88(2):231-4. PubMed ID: 25736571
    [Abstract] [Full Text] [Related]

  • 18. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
    Ou SH, Klempner SJ, Greenbowe JR, Azada M, Schrock AB, Ali SM, Ross JS, Stephens PJ, Miller VA.
    J Thorac Oncol; 2014 Dec 01; 9(12):1821-5. PubMed ID: 25393796
    [Abstract] [Full Text] [Related]

  • 19. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
    Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Balas B, Puig O, Henschel V, Ou SI, study investigators.
    Lancet Oncol; 2016 Feb 01; 17(2):234-242. PubMed ID: 26708155
    [Abstract] [Full Text] [Related]

  • 20. Alectinib Approved for ALK+ Lung Cancer.
    Cancer Discov; 2016 Feb 01; 6(2):115. PubMed ID: 26739884
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.